References
- Feldman, E.C., Nelson, R.W. (2004). Canine hyperadrenocorticism Cushings syndrome. In: Canine and Feline Endocrinology and Reproduction (p. 252). Elsevier Health Sciences.
- Kritsepi-Konstantinou, M., Oikonomidis, I.L. (2016). The interpretation of leukogram in dog and cat. HJCAM 5(2): 63.
- Ryad, N.M., Ramadan, E.S., Salem, N.Y., Saleh, I.A. (2021). Influence of dexamethasone administration on hematology, biochemistry, and thyroid hormones in dogs. Adv Anim Vet Sci. 9(1): 111-116. https://doi.org/10.17582/journal.aavs/2021/9.1.111.116
- Peterson, M.E. (2007). Diagnosis of hyperadrenocorticism in dogs. Clin Tech Small Anim Pract. 22(1): 2-11. https://doi.org/10.1053/j.ctsap.2007.02.007 PMid:17542191
- Behrend, E.N., Kooistra, H.S., Nelson, R., Reusch, C.E., Scott‐Moncrieff, J.C. (2013). Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM consensus statement (small animal). J Vet Intern Med. 27(6): 1292-1304. https://doi.org/10.1111/jvim.12192 PMid:24112317
- Potts, G.O., Creange, J.E., Harding, H.R., Schane, H.P. (1978). Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids 32(2): 257-267. https://doi.org/10.1016/0039-128X(78)90010-7 PMid:715820
- Eastwood, J.M., Elwood, C.M., Hurley, K.J. (2003). Trilostane treatment of a dog with functional adrenocortical neoplasia. J Small Anim Pract. 44(3): 126-131. https://doi.org/10.1111/j.1748-5827.2003.tb00133.x PMid:12653328
- Neiger, R., Hurley, K.J., Ramsey, I., O’Connor, J., Mooney, C.T. (2002). Trilostane treatment of 78 dogs with pituitary‐dependent hyperadrenocorticism. Vet Rec. 150(26): 799-804. https://doi.org/10.1136/vr.150.26.799 PMid:12120922
- Lemetayer, J., Blois, S. (2018). Update on the use of trilostane in dogs. Can Vet J. 59(4): 397-407.
- Bell, R., Neiger, R., McGrotty, Y., Ramsey, I.K. (2006). Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs. Vet Rec. 159(9): 277-281. https://doi.org/10.1136/vr.159.9.277 PMid:16946310
- Vaughan, M.A., Feldman, E.C., Hoar, B.R., Nelson, R.W. (2008). Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocor ticism. J Am Vet Med Assoc. 232(9): 1321-1328. https://doi.org/10.2460/javma.232.9.1321 PMid:18447776
- Feldman, E.C. (2011). Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. J Am Vet Med Assoc. 238(11): 1441-1451. https://doi.org/10.2460/javma.238.11.1441 PMid:21627507
- Teshima, T., Hara, Y., Takekoshi, S., Nezu, Y., Harada, Y., Yogo, T., Teramoto, A., Osaamura, R.Y., Tagawa, M. (2009). Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic-pituitary axis. Domest Anim Endocrinol. 36(1): 32-44. https://doi.org/10.1016/j.domaniend.2008.10.002 PMid:19041802
- Gilor, C., Graves, T.K. (2011). Interpretation of laboratory tests for canine Cushing’s syndrome. Top Companion Anim Med. 26(2): 98-108. https://doi.org/10.1053/j.tcam.2011.03.001 PMid:21596349
- Fathman, L. (2005). Textbook of veterinary internal medicine. Elsevier Saunders
- Jacoby, R.C., Owings, J.T., Ortega, T., Gosselin, R., Feldman, E.C. (2001). Biochemical basis for the hypercoagulable state seen in Cushing syndrome; discussion 1006-7. Arch Surg. 136(9): 1003-1006. https://doi.org/10.1001/archsurg.136.9.1003 PMid:11529821
- Galac, S. (2010). Recent developments in canine Cushings syndrome. Utrecht University
- Cho, K.D., Kang, J.H., Chang, D., Na, K.J., Yang, M.P. (2013). Efficacy of low‐ and high‐dose trilostane treatment in dogs (<5 kg) with pituitary‐dependent hyperadrenocorticism. J Vet Intern Med. 27(1): 91-98. https://doi.org/10.1111/jvim.12007 PMid:23167780
- Ettinger, S.J., Feldman, E.C. (2010). Textbook of veterinary internal medicine. 7th edition, 2086-2088.
- Alenza, D.P., Arenas, C., Lopez, M.L., Melian, C. (2006). Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism. J Am Anim Hosp Assoc. 42(4): 269-276. https://doi.org/10.5326/0420269 PMid:16822765